enGene (ENGN) announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to detalimogene voraplasmid, the company’s investigational therapy for the treatment of high-risk, Bacillus Calmette-Guerin-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Optimistic Buy Rating for enGene Holdings Amid LEGEND Study Progress and Regulatory Advancements
- enGene price target lowered to $19 from $34 at Morgan Stanley
- enGene Holdings Reports Q2 2025 Financial Results
- enGene Holdings Approves 2025 Employee Stock Purchase Plan
- enGene Holdings Expands with New Boston Lease